BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 30373620)

  • 21. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents.
    Dybul M; Fauci AS; Bartlett JG; Kaplan JE; Pau AK;
    Ann Intern Med; 2002 Sep; 137(5 Pt 2):381-433. PubMed ID: 12617573
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Recommendations of the Panel on Clinical Practices for Treatment of HIV.
    Dybul M; Fauci AS; Bartlett JG; Kaplan JE; Pau AK;
    MMWR Recomm Rep; 2002 May; 51(RR-7):1-55. PubMed ID: 12027060
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Optimal monitoring strategies for guiding when to switch first-line antiretroviral therapy regimens for treatment failure in adults and adolescents living with HIV in low-resource settings.
    Chang LW; Harris J; Humphreys E
    Cochrane Database Syst Rev; 2010 Apr; (4):CD008494. PubMed ID: 20393969
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness and tolerance of single tablet versus once daily multiple tablet regimens as first-line antiretroviral therapy - Results from a large french multicenter cohort study.
    Cotte L; Ferry T; Pugliese P; Valantin MA; Allavena C; Cabié A; Poizot-Martin I; Rey D; Duvivier C; Cheret A; Dellamonica P; Pradat P; Parienti JJ;
    PLoS One; 2017; 12(2):e0170661. PubMed ID: 28152047
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A single tablet regimen is associated with higher adherence and viral suppression than multiple tablet regimens in HIV+ homeless and marginally housed people.
    Bangsberg DR; Ragland K; Monk A; Deeks SG
    AIDS; 2010 Nov; 24(18):2835-40. PubMed ID: 21045636
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a systematic review and meta-analysis.
    Jiang HY; Zhang MN; Chen HJ; Yang Y; Deng M; Ruan B
    Int J Infect Dis; 2014 Aug; 25():130-5. PubMed ID: 24911886
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relationship Between Single Tablet Antiretroviral Regimen and Adherence to Antiretroviral and Non-Antiretroviral Medications Among Veterans' Affairs Patients with Human Immunodeficiency Virus.
    Yager J; Faragon J; McGuey L; Hoye-Simek A; Hecox Z; Sullivan S; Neubert S; Patel N
    AIDS Patient Care STDS; 2017 Sep; 31(9):370-376. PubMed ID: 28771023
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
    Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
    Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Persistence and adherence to single-tablet regimens in HIV treatment: a cohort study from the French National Healthcare Insurance Database.
    Raffi F; Yazdanpanah Y; Fagnani F; Laurendeau C; Lafuma A; Gourmelen J
    J Antimicrob Chemother; 2015 Jul; 70(7):2121-8. PubMed ID: 25904729
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of a single-tablet regimen containing tenofovir disoproxil fumarate 300 mg, lamivudine 300 mg and efavirenz 400 mg as a switch strategy in virologically suppressed HIV-1-infected subjects on nonnucleoside reverse transcriptase inhibitor-containing first-line antiretroviral therapy in Pune, India.
    Dravid A; Betha TP; Sharma AK; Gawali R; Mahajan U; Kulkarni M; Saraf C; Kore S; Dravid M; Rathod N
    HIV Med; 2020 Oct; 21(9):578-587. PubMed ID: 33021066
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study.
    Lataillade M; Lalezari JP; Kozal M; Aberg JA; Pialoux G; Cahn P; Thompson M; Molina JM; Moreno S; Grinsztejn B; Diaz RS; Castagna A; Kumar PN; Latiff GH; De Jesus E; Wang M; Chabria S; Gartland M; Pierce A; Ackerman P; Llamoso C
    Lancet HIV; 2020 Nov; 7(11):e740-e751. PubMed ID: 33128903
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness, Safety, and Costs of Dolutegravir/Abacavir/Lamivudine Single-Tablet Regimen in a Real-Life Cohort of HIV-1 Adult Infected Patients.
    Rodriguez-Gonzalez CG; Chamorro-de-Vega E; Ortega-Navarro C; Alonso R; Herranz-Alonso A; Sanjurjo-Saez M
    Ann Pharmacother; 2020 Jul; 54(7):633-643. PubMed ID: 31910643
    [No Abstract]   [Full Text] [Related]  

  • 33. Cost analysis of initial highly active antiretroviral therapy regimens for managing human immunodeficiency virus-infected patients according to clinical practice in a hospital setting.
    Colombo GL; Castagna A; Di Matteo S; Galli L; Bruno G; Poli A; Salpietro S; Carbone A; Lazzarin A
    Ther Clin Risk Manag; 2014; 10():9-15. PubMed ID: 24379676
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increase in single-tablet regimen use and associated improvements in adherence-related outcomes in HIV-infected women.
    Hanna DB; Hessol NA; Golub ET; Cocohoba JM; Cohen MH; Levine AM; Wilson TE; Young M; Anastos K; Kaplan RC
    J Acquir Immune Defic Syndr; 2014 Apr; 65(5):587-96. PubMed ID: 24326606
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study.
    García F; Romeu J; Grau I; Sambeat MA; Dalmau D; Knobel H; Gomez-Sirvent JL; Arrizabalaga J; Cruceta A; Clotet BG; Podzamczer D; Pumarola T; Gallart T; O'Brien WA; Miró JM; Gatell JM
    AIDS; 1999 Dec; 13(17):2377-88. PubMed ID: 10597779
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structured treatment interruptions (STI) in chronic unsuppressed HIV infection in adults.
    Pai NP; Lawrence J; Reingold AL; Tulsky JP
    Cochrane Database Syst Rev; 2006 Jul; 2006(3):CD006148. PubMed ID: 16856117
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efavirenz versus nevirapine-based initial treatment of HIV infection: clinical and virological outcomes in Southern African adults.
    Nachega JB; Hislop M; Dowdy DW; Gallant JE; Chaisson RE; Regensberg L; Maartens G
    AIDS; 2008 Oct; 22(16):2117-25. PubMed ID: 18832875
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Single-tablet regimens in HIV: does it really make a difference?
    Aldir I; Horta A; Serrado M
    Curr Med Res Opin; 2014 Jan; 30(1):89-97. PubMed ID: 24040862
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Determinants of discontinuation of initial highly active antiretroviral therapy regimens in a US HIV-infected patient cohort.
    Yuan Y; L'italien G; Mukherjee J; Iloeje UH
    HIV Med; 2006 Apr; 7(3):156-62. PubMed ID: 16494629
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adherence to HIV treatment regimens: systematic literature review and meta-analysis.
    Altice F; Evuarherhe O; Shina S; Carter G; Beaubrun AC
    Patient Prefer Adherence; 2019; 13():475-490. PubMed ID: 31040651
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.